Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice

OBJECTIVE: Inflammatory bowel diseases (IBD) have been intrinsically linked to a deregulated cytokine network, but novel therapeutic principles are urgently needed. Here we identify the interleukin (IL)-33 and its receptor ST2 as key negative regulators of wound healing and permeability in the colon...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedhom, Mamdouh A K, Pichery, Mélanie, Murdoch, Jenna R, Foligné, Benoit, Ortega, Nathalie, Normand, Sylvain, Mertz, Kirsten, Sanmugalingam, Devika, Brault, Lea, Grandjean, Teddy, Lefrancais, Emma, Fallon, Padraic G, Quesniaux, Valérie, Peyrin-Biroulet, Laurent, Cathomas, Gieri, Junt, Tobias, Chamaillard, Mathias, Girard, Jean-Philippe, Ryffel, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Experimental Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841767/
https://www.ncbi.nlm.nih.gov/pubmed/23172891
http://dx.doi.org/10.1136/gutjnl-2011-301785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841767/
https://www.ncbi.nlm.nih.gov/pubmed/23172891
http://dx.doi.org/10.1136/gutjnl-2011-301785

Ejemplares similares